Processa CAO buys 1,748 shares of common stock

Processa Pharmaceuticals Chief Administrative Officer Wendy Guy reported an open-market purchase of the company’s common stock.

Rhea-AI Filing Summary

Processa Pharmaceuticals Chief Administrative Officer Wendy Guy reported an open-market purchase of the company’s common stock. On April 30, 2026, she bought 1,748 shares of Processa Pharmaceuticals, Inc. common stock at $2.69 per share in a direct transaction.

Following this purchase, she directly owns 6,441 common shares. The filing also lists an indirect holding of 333 common shares described as held "By CorLyst, LLC," reflecting a separate ownership line associated with her.

Insider Trade Summary

Net Buyer: 1,748 shares

Net Buy 2 txns

Insider Guy Wendy

Role Chief Administrative Officer

Bought 1,748 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,748	$2.69	$5K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 6,441 shares (Direct); Common Stock — 333 shares (Indirect, By CorLyst, LLC)

Key Figures

Shares purchased: 1,748 shares Purchase price: $2.69 per share Direct holdings after trade: 6,441 shares +1 more

4 metrics

Shares purchased 1,748 shares Open-market purchase of common stock on April 30, 2026

Purchase price $2.69 per share Price for non-derivative common stock acquisition

Direct holdings after trade 6,441 shares Common stock directly owned following the purchase

Indirect holdings 333 shares Common stock held indirectly by CorLyst, LLC

Key Terms

open-market purchase, indirect ownership, Common Stock, Form 4

4 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

""direct_or_indirect": "I", "nature_of_ownership": "By CorLyst, LLC""

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Processa Pharmaceuticals (PCSA) report for Wendy Guy?

Processa Pharmaceuticals reported that Chief Administrative Officer Wendy Guy bought 1,748 shares of common stock in an open-market transaction. The trade occurred on April 30, 2026, and is disclosed on a Form 4 insider filing with the SEC.

How many Processa Pharmaceuticals (PCSA) shares did Wendy Guy purchase and at what price?

Wendy Guy purchased 1,748 shares of Processa Pharmaceuticals common stock at a price of $2.69 per share. This open-market transaction is recorded as a non-derivative acquisition and reflects a direct purchase of the company’s common shares.

What are Wendy Guy’s Processa Pharmaceuticals (PCSA) holdings after this Form 4 transaction?

After the reported transaction, Wendy Guy directly owns 6,441 shares of Processa Pharmaceuticals common stock. The filing also shows an additional 333 common shares held indirectly through CorLyst, LLC, listed as a separate ownership entry associated with her.

What does indirect ownership by CorLyst, LLC mean in the Processa (PCSA) Form 4?

The Form 4 shows 333 Processa Pharmaceuticals common shares held indirectly "By CorLyst, LLC." This indicates those shares are owned through that entity rather than in Wendy Guy’s personal name, and the filing attributes this indirect position to her.

Was the Processa Pharmaceuticals (PCSA) insider transaction a buy or a sell?

The reported insider transaction was a buy. The Form 4 lists a transaction code "P" for Wendy Guy’s acquisition of 1,748 Processa Pharmaceuticals common shares, indicating an open-market purchase rather than a sale or derivative-related transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 04:35 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guy Wendy

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Administrative Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/30/2026		P		1,748	A	$2.69	6,441	D
Common Stock								333	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Wendy Guy by John J. Wolfel, as Attorney-in-Fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)